Want to see BCLI full AI Analyst Report?
Brainstorm Cell Therapeutics (BCLI) Financial Statements
Brainstorm Cell Therapeutics Financial Overview
Brainstorm Cell Therapeutics's market cap is currently $9.49M. The company's EPS TTM is $-0.95; its P/E ratio is -0.91; Brainstorm Cell Therapeutics is estimated to report earnings on November 16, 2026, and the estimated EPS forecast is $-0.18. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Mar 25 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -240.00K | $ -265.00K | $ -285.00K | $ -260.00K |
| Operating Income | $ -9.95M | $ -11.69M | $ -21.44M | $ -24.82M | $ -24.54M |
| EBITDA | $ -9.75M | $ -11.31M | $ -16.93M | $ -23.99M | $ -24.28M |
| Net Income | $ -10.31M | $ 11.62M | $ -17.19M | $ -24.28M | $ -24.46M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 29.00K | $ 187.00K | $ 1.30M | $ 2.98M | $ 22.09M |
| Total Assets | $ 715.00K | $ 1.83M | $ 4.21M | $ 8.45M | $ 29.28M |
| Total Debt | $ 208.00K | $ 720.00K | $ 1.27M | $ 4.09M | $ 5.08M |
| Net Debt | $ 179.00K | $ 533.00K | $ -25.00K | $ 3.32M | $ -13.78M |
| Total Liabilities | $ 11.01M | $ 9.60M | $ 9.07M | $ 11.47M | $ 9.94M |
| Stockholders' Equity | $ -10.29M | $ -7.76M | $ -4.86M | $ -3.02M | $ 19.34M |
| Cash Flow | |||||
| Free Cash Flow | $ -6.97M | $ -9.09M | $ -20.48M | $ -19.35M | $ -26.59M |
| Operating Cash Flow | $ -6.97M | $ -9.09M | $ -20.46M | $ -19.32M | $ -26.27M |
| Investing Cash Flow | $ 0.00 | $ 12.00K | $ 2.19M | $ 998.00K | $ 323.00K |
| Financing Cash Flow | $ 6.88M | $ 7.97M | $ 18.98M | $ 238.00K | $ 6.97M |
Currency in USD
